Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14001646 | 0.88 | SPHK1 (0.54) | SPHK1SLC6A4MAP1LC3BSLC6A2SLC6A3 | |
| SCHEMBL1405569 | 0.76 | ESR2 (0.50) | MAP1LC3BHTR2ALMNACYP3A4CYP2C9 | |
| SCHEMBL735534 | 0.75 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL20063877 | 0.75 | MAP1LC3B (0.36) | SPHK1MAP1LC3BHTR2ALMNACYP3A4 | |
| SCHEMBL7973077 | 0.75 | ALOX5 (0.40) | MAP1LC3BLMNACYP3A4CYP2C9HRH3 | |
| SCHEMBL7972773 | 0.75 | ALOX5 (0.40) | MAP1LC3BLMNACYP3A4CYP2C9HRH3 | |
| SCHEMBL12398749 | 0.75 | SLC6A4 (0.36) | SLC6A4HTR1ADRD1SLC6A2HTR1B | |
| SCHEMBL7973079 | 0.75 | ALOX5 (0.40) | MAP1LC3BLMNACYP3A4CYP2C9HRH3 | |
| SCHEMBL7972771 | 0.75 | ALOX5 (0.40) | MAP1LC3BLMNACYP3A4CYP2C9HRH3 | |
| SCHEMBL7972772 | 0.75 | ALOX5 (0.40) | MAP1LC3BLMNACYP3A4CYP2C9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138377-B2 | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use | DOV PHARMACEUTICAL, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080293822-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080269348-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194696-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194696-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | SPHK1 3028/4885SLC6A4 93/4885MAP1LC3B 1307/4885 |
| US-20080293822-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | SPHK1 3028/4885SLC6A4 93/4885MAP1LC3B 1307/4885 |
| US-20080269348-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | SPHK1 3028/4885SLC6A4 93/4885MAP1LC3B 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.